AbbVie signed a deal to acquire ex‑China rights to Zelgen Biopharmaceuticals’ trispecific T‑cell engager alveltamig (ZG‑006) in a pact valued at up to $1.1 billion. Under the agreement, AbbVie will pay $100 million up front, Zelgen can receive $60 million in near‑term milestones and up to $1.075 billion in additional development, regulatory and commercial milestones, plus tiered royalties on sales outside China. The transaction hands AbbVie a next‑generation DLL3‑targeting multispecific antibody program and gives Zelgen cash and retained China rights to continue development and commercialization locally. BioCentury reported the terms and framed the move as a rapid marketplay for multispecific T‑cell engagers as big pharma pursues high‑value oncology assets.